Biophytis Publishes First-Half Financial Results and Provides an Update on its Business Activities
Biophytis publishes its financial results for the first half of 2024 and provides an update on the company’s key achievements.
Stanislas Veillet, CEO of Biophytis, commented: u201cWe are particularly pleased with the progress made in the first half of 2024. The launch of our clinical program OBA for obesity, addressing a major public health issue, and our partnership with Blanver to develop BIO101 in Latin America, are key milestones that demonstrate Biophytis’ ability to innovate and capitalize on market opportunities.
We are now entering a critical phase where the results of our clinical trials, especially in the obesity field, along with our continued strategy of regional pharmaceutical partnerships, particularly in Asia, could significantly transform the company’s future.
Despite the ongoing challenges in financial markets, the Company has been able to extend its bond financing line, and is actively working on recapitalization solutions to support its future growth.u201d
